Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1664-9.

2.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH.

Neurology. 2002 May 14;58(9):1404-7.

PMID:
12011290
3.

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group..

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468.

PMID:
22791906
4.

The effect of cannabis on tremor in patients with multiple sclerosis.

Fox P, Bain PG, Glickman S, Carroll C, Zajicek J.

Neurology. 2004 Apr 13;62(7):1105-9.

PMID:
15079008
6.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Rog DJ, Nurmikko TJ, Friede T, Young CA.

Neurology. 2005 Sep 27;65(6):812-9.

PMID:
16186518
7.

Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.

Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):41-7. doi: 10.1097/WNF.0B013E3181633497.

PMID:
18978501
8.

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.

Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

9.

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group..

Lancet. 2003 Nov 8;362(9395):1517-26.

PMID:
14615106
10.

Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.

Vakhapova V, Auriel E, Karni A.

Clin Neuropharmacol. 2010 May;33(3):151-4. doi: 10.1097/WNF.0b013e3181daad7d.

PMID:
20502134
11.

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.

Cannabis-In-Cachexia-Study-Group., Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T.

J Clin Oncol. 2006 Jul 20;24(21):3394-400.

PMID:
16849753
12.
13.
15.

Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.

Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM.

J Clin Psychiatry. 2003 Apr;64(4):459-65.

PMID:
12716250
17.

[Long-term effects of glatiramer acetate in multiple sclerosis].

Brochet B.

Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. French.

PMID:
18790510
18.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group..

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
19.

A randomized trial of memantine as treatment for spasticity in multiple sclerosis.

Mehta LR, McDermott MP, Goodman AD, Schwid SR.

Mult Scler. 2010 Feb;16(2):248-51. doi: 10.1177/1352458509355462.

PMID:
20028712

Supplemental Content

Support Center